X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5020) 5020
Book Review (791) 791
Publication (665) 665
Book Chapter (35) 35
Conference Proceeding (25) 25
Dissertation (22) 22
Government Document (2) 2
Magazine Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3625) 3625
humans (2984) 2984
jak2 (2318) 2318
hematology (1854) 1854
polycythemia-vera (1536) 1536
mutation (1524) 1524
janus kinase 2 - genetics (1351) 1351
essential thrombocythemia (1269) 1269
oncology (1232) 1232
female (1222) 1222
male (1209) 1209
animals (1159) 1159
tyrosine kinase jak2 (1129) 1129
myeloproliferative disorders (951) 951
middle aged (866) 866
myeloproliferative neoplasms (833) 833
myelofibrosis (799) 799
aged (755) 755
adult (741) 741
mice (696) 696
janus kinase 2 - metabolism (669) 669
janus kinase 2 (667) 667
myeloproliferative disorders - genetics (630) 630
signal transduction (582) 582
genetic aspects (511) 511
phosphorylation (499) 499
biochemistry & molecular biology (494) 494
jak2 v617f mutation (491) 491
polycythemia vera (488) 488
cell biology (472) 472
activation (469) 469
expression (461) 461
aged, 80 and over (458) 458
leukemia (439) 439
abridged index medicus (412) 412
janus kinase 2 - antagonists & inhibitors (404) 404
hemic and lymphatic diseases (399) 399
myeloid metaplasia (398) 398
research (393) 393
apoptosis (391) 391
cancer (371) 371
polycythemia vera - genetics (370) 370
primary myelofibrosis (366) 366
tumors (365) 365
thrombocythemia, essential - genetics (363) 363
analysis (360) 360
stat3 (354) 354
disorders (342) 342
prognosis (325) 325
primary myelofibrosis - genetics (320) 320
diagnosis (314) 314
signal transduction - drug effects (310) 310
article (309) 309
thrombosis (306) 306
jak2 mutation (304) 304
cell line, tumor (297) 297
risk factors (294) 294
health aspects (291) 291
cells (285) 285
chronic myeloproliferative disorders (272) 272
care and treatment (268) 268
activating mutation (266) 266
jak2 inhibitor (264) 264
jak2 v617f (255) 255
pharmacology & pharmacy (255) 255
adolescent (254) 254
stat3 transcription factor - metabolism (254) 254
kinases (248) 248
proteins (248) 248
cell line (245) 245
gene expression (242) 242
medicine, research & experimental (240) 240
pathology (239) 239
hematology, oncology and palliative medicine (236) 236
young adult (229) 229
ruxolitinib (228) 228
acute myeloid-leukemia (221) 221
medicine & public health (221) 221
gene mutations (219) 219
polycythemia (217) 217
mutations (214) 214
v617f mutation (214) 214
protein-tyrosine kinases - metabolism (212) 212
jak2/stat3 (211) 211
rats (209) 209
disease (206) 206
protein kinase inhibitors - pharmacology (206) 206
cells, cultured (202) 202
myeloproliferative disorders - pathology (198) 198
myeloproliferative neoplasm (196) 196
alleles (194) 194
receptor (192) 192
mutation, missense (191) 191
neoplasms (191) 191
myeloproliferative disorders - diagnosis (188) 188
immunology (187) 187
jak2v617f (185) 185
cytokines (183) 183
amino acid substitution (180) 180
point mutation (180) 180
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4871) 4871
French (45) 45
Japanese (29) 29
Spanish (22) 22
German (20) 20
Korean (18) 18
Chinese (15) 15
Polish (13) 13
Russian (13) 13
Hungarian (12) 12
Czech (4) 4
Turkish (4) 4
Slovenian (3) 3
Portuguese (2) 2
Slovak (2) 2
Italian (1) 1
Persian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BLOOD, ISSN 0006-4971, 07/2007, Volume 110, Issue 1, pp. 375 - 379
To study the role of the JAK2-V617F mutation in leukemic transformation, we examined 27 patients with myeloproliferative disorders (MPDs) who transformed to... 
TRANSFORMATION | POLYCYTHEMIA-VERA | ACTIVATING MUTATION | JAK2(V617F) MUTATION | TYROSINE KINASE JAK2 | JAK2 V617F MUTATION | ACUTE MYELOID-LEUKEMIA | MYELODYSPLASTIC-SYNDROMES | ESSENTIAL THROMBOCYTHEMIA | DIAGNOSTIC-CRITERIA | HEMATOLOGY
Journal Article
Oncotarget, ISSN 1949-2553, 10/2018, Volume 9, Issue 81, pp. 35201 - 35202
Journal Article
Journal Article
Anticancer Research, ISSN 0250-7005, 07/2017, Volume 37, Issue 7, pp. 3841 - 3847
Background/Aim: In myeloproliferative neoplasms (MPN), Janus kinase 2 (JAK2) is activated by mutations including JAK2V617F (JAK2VF). It is unclear whether JAK... 
Animal models | JAK2 inhibitors | TYK2 | JAK2 | Myeloproliferative neoplasms | MYELOFIBROSIS | animal models | JAK2 INHIBITOR | ONCOLOGY | INHIBITOR THERAPY | CHRONIC MYELOID-LEUKEMIA | RUXOLITINIB | Index Medicus
Journal Article
Oncotarget, ISSN 1949-2553, 11/2018, Volume 9, Issue 87, pp. 35721 - 35722
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2005, Volume 131, Issue 2, pp. 208 - 213
Summary Clinical correlates and long-term prognostic relevance of the JAK2V617F mutation was studied in 150 patients with essential thrombocythaemia (ET) from... 
JAK2 mutation | myeloproliferative disorders | prognosis | essential thrombocythaemia | Prognosis | Essential thrombocythaemia | Myeloproliferative disorders
Journal Article
Medical Oncology, ISSN 1357-0560, 05/2017, Volume 34, Issue 5, pp. 95 - 95
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s12032-017-0957-7 
ONCOLOGY | JAK2 | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 03/2014, Volume 123, Issue 10, pp. 1552 - 1555
Journal Article
Clinical Lymphoma Myeloma and Leukemia, ISSN 2152-2650, 09/2017, Volume 17, pp. S91 - S92
Journal Article
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, ISSN 0390-6078, 01/2008, Volume 93, Issue 1, pp. 41 - 48
Background Fifty to sixty percent of patients with essential thrombocythemia harbor the JAK2(V617F) mutation. The impact of this mutation on clinical phenotype... 
phenotype | JAK2(V617F) | POLYCYTHEMIA-VERA | MYELOPROLIFERATIVE DISORDERS | JAK2 V617F MUTATION | CHROMOSOME INACTIVATION PATTERNS | RISK | ACTIVATING MUTATION | essential thrombocythemia | TYROSINE KINASE JAK2 | allele burden | 617V-GREATER-THAN-F MUTATION | HEMATOLOGY | MYELOID METAPLASIA | FEMALE-PATIENTS
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2005, Volume 131, Issue 3, pp. 320 - 328
Summary An association between an activating JAK2 mutation (JAK2V617F) and BCR/ABL-negative myeloproliferative disorders was recently reported in multiple... 
mutation | Myelofibrosis | clonality | JAK2 | prognosis | polycythaemia vera | Clonality | Polycythaemia vera | Prognosis | Mutation
Journal Article
Phytomedicine, ISSN 0944-7113, 08/2019, Volume 61, pp. 152848 - 152848
2-hydroxy-3-methylanthraquinone (HMA), an anthraquinone monomer in traditional Chinese medicine , has been reported to inhibit the growth of several types of... 
2-Hydroxy-3-methylanthraquinone | Human lung carcinoma | IL-6, JAK2/STAT3
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2015, Volume 136, Issue 3, pp. 547 - 559
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.